Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)
Close on Nov 17, 2026Market cap $1.57BP/E –Yield –
Vir Biotechnology price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Vir Biotechnology's price to book ratio was 2.3× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 0.7× to 9.4×, with a median of 1.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.3× | +1.2 |
| 2025 | Dec 31, 2025 | 1.1× | +0.2 |
| 2024 | Dec 31, 2024 | 0.8× | −0.1 |
| 2023 | Jul 31, 2023 | 1.0× | −0.6 |
| 2022 | Dec 30, 2022 | 1.6× | −4.7 |
| 2021 | Dec 31, 2021 | 6.3× | +2.1 |
| 2020 | Dec 31, 2020 | 4.2× | – |
See a number that looks wrong?